Volume 132, Issue 20



November 15, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: The dynamic process of Charcot-Leyden crystal formation. See the article by Ueki et al.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
van Rhee and colleagues present consensus guidelines for treating idiopathic multicentric Castleman disease based on a review of treatment and response in 344 cases. They focus on the role of steroids, cytokine suppression, chemotherapy, and immunomodulatory agents.

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
Chapman et al identify a therapeutically useful 7-gene RNA expression signature in myeloma that predicts better response to bortezomib and worse response to lenalidomide.

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
In this month’s CME article, Jestin and colleagues demonstrate that rituximab administered to patients who do not fully recover ADAMTS13 activity or who have recurrent loss of ADAMTS13 activity prevents long-term relapse of thrombocytopenic purpura.

Molecular monitoring in CML: how deep? How often? How should it influence therapy?
Shanmuganathan and Hughes use 3 illustrative cases to review the approach to molecular monitoring in chronic myeloid leukemia (CML) with focus on assessment of treatment response, safety of therapy discontinuation, and signals mandating changing tyrosine kinase inhibitors.

Evaluation and management of heavy menstrual bleeding in adolescents: the role of the hematologist
O’Brien addresses the dilemma of heavy menstrual bleeding in adolescents, focusing on appropriate evaluation, treatment of concomitant iron deficiency, and strategies for minimizing bleeding.

Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death
Ueki and colleagues demonstrate that the formation of Charcot-Leyden crystals in tissue is a dynamic process reflecting release of galectin-10 from eosinophils undergoing cytolysis through extracellular trap formation.

Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice
Radojcic et al confirm the role of Notch signaling in murine graft-versus-host disease (GVHD). They demonstrate that antibodies targeting the Notch ligands DLL1 and DLL4 reduce GVHD, offering a potential GVHD prevention strategy that avoids the side effects associated with broader Notch pathway inhibition.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.